Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer

  • Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14)
  • METex14 is an important biomarker for physicians to consider when selecting metastatic NSCLC treatment options1
     
  • In the US, METex14 metastatic NSCLC is diagnosed in ~4,000-5,000 patients annually and typically indicates aggressive disease with a poor prognosis2-3

Basel, …

/by

AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

Novartis has renamed the previously acquired AveXis to Novartis Gene Therapies. The change signifies the growing importance of gene therapy to building a leading, focused medicines company with advanced therapy platforms.

Building on the success of Zolgensma® (onasemnogene abeparvovec), Novartis Gene Therapies will be responsible for the research, development, manufacturing and commercialization of the next wave of AAV-based innovative gene therapies. Novartis Gene Therapies will also provide manufacturing support for gene therapy work conducted by other Novartis units. Dave Lennon, …

/by

New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines

  • The collaboration aims to help alleviate supply and logistical constraints in the African Union member states
     
  • Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero-profit to governments through Africa Medical Supplies Platform (AMSP) to 55 African and 15 Caricom eligible countries
     
  • The African Union through the AMSP has integrated vetted medical suppliers to ensure rapid access to affordable COVID-19 related supplies

Basel, …

/by

Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality

  • 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential reach to over 23 million patients across these initiatives
     
  • Enhanced target for full carbon neutrality across all company operations and entire supply chain by 20301
     
  • New collaboration with the African Union initiated Africa Medical Supplies Platform to aid supply of Novartis COVID-19 Pandemic Response Portfolio
     
  • Company completed …
/by

Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

  • Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran) 1
     
  • New post-hoc analysis demonstrates 99% of patients treated with inclisiran showed placebo-adjusted reduction in low-density lipoprotein cholesterol (LDL-C) of ≥30% with a mean reduction of 54.1% from baseline (observed values)2
     
  • 88% of inclisiran-treated patients achieved LDL-C …
/by

Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)

  • Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab

  • Seven of ten patients discontinued eculizumab and remained on LNP023 as monotherapy, retaining hemoglobin (Hb) levels with no changes in biomarkers of disease activity and with no signs or symptoms of breakthrough hemolysis
     
  • Phase II results are promising for treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder;1,2 second Phase …
/by

50 Climate Leaders

Windfarm to neutralize carbon footprint in USA and Canada.

Human health is inextricably linked to planetary health. As the impacts of climate change are being experienced around the globe, the impacts on global health are becoming more and more clear.

Heat events and …

/by

Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study

  • At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with two or more tyrosine-kinase inhibitors (TKIs)1
     
  • Despite advances in chronic myeloid leukemia (CML) care, many patients are at risk of disease progression, and sequential TKI therapy may be associated with increased resistance and intolerance2-7
     
  • By specifically targeting the ABL myristoyl pocket, STAMP inhibition has …
/by

Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma

  • Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma
  • Tafinlar + Mekinist remains an effective treatment option based on previously reported large, Phase III clinical trials1,2
     
  • Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents

Basel, August 22, 2020 — Novartis announced today that the Phase III COMBI-i study evaluating the investigational immunotherapy …

/by

Building collaborations to fight a pandemic

As an expert in infectious diseases, Jennifer Leeds could see the storm brewing. When COVID-19 began to emerge – first in Asia, then in Europe – she could see that its relative ease transmitting from person to person, along with the lack of tests and preventions or treatments for infection, made the virus a credible threat to humanity. Knowing that a pandemic was likely coming made watching the crisis unfold no less heartbreaking. Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help.

…

/by